It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
An interesting story on what a DNA report can reveal, in this case the woman has an X and a Y, instead of two Xs, like most females. It is somewhat rare but does exist with having internal testicles, and this produces extra high levels of estrogen, the the testosterone produced pretty much can't...
Pfizer is wasting no time to get the calculations running and numbers rolling. To stay in the market, they are attempting to find out as much as they can about potential side effects and other perhaps adverse affects of their drugs. Better than they find up them front, as it will make for better...
The company, Accium Biosciences runs a device called a spectrometer, and it qualifies the amount of c-14, present in a sample, so what does all this mean? The sample gives information relative to the drug makers as to how the drugs are working, big news coinciding with personalized medicine. This...
The article states it was about time to update the female side of things after successfully sequencing 4 males...we all know the female side of things is just a big more complicated...BD Dutch scientists said they have completed the first sequencing of an individual woman's DNA. The researchers at...
If you have not read up yet on personalized medicine this is a great article that will go through the basics in layman's terms...there are 4 links below to each section...and the last area is the toughest...the challenges as it will all be work in progress for quite a while to come...so somebody...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
05-24-2008
Filed under:
Filed under: Medically Related, Technology, Insurance, Pharma/FDA News, Labs, personalized medicine, Medicine, DNA, Biotech, healthcare providers, Advocates